ACE2 is the entry receptor of SARS-CoV-2 (Oudit et al., 2023), APOE genotype was associated with survival in patients infected with COVID19 (Ostendorf et al., 2022) and E4 was associated with severe COVID19 with more prevalent microhemorrhages in intensive care patients (Kurki et al., 2021). This evidence concerns the gene ACE2 and COVID-19.